Fox (Michael J.) Foundation for Parkinson's Research

Funding Organization

Awards Grant

  • 14-3-3 Phosphorylation as a Biomarker for Parkinson's Disease
  • 14-3-3 Phosphorylation as a Biomarker for Parkinson's Disease
  • 14-3-3s as Regulators of LRRK2 Toxicity
  • A Diffusion Tensor Based Biomarker for Parkinson's Disease
  • Advancing PINK1 KO Rat Animal Models of PD
  • Advancing PINK1 KO Rat Animal Models of PD
  • Alpha-Galactosidase A and Glycosphingolipid Metabolites as Putative Biomarkers for PD
  • Alpha-Galactosidase A as a Therapeutic Target for Parkinson's Disease
  • Analysis of Parkin Activity in W403A Parkin Knockin Mice
  • Characterization of the in Vivo Effects of aSyn PFFs on Mouse Brain Mitochondria
  • Clinician-Input Study: How the Fox Insight Mobile Application can Influence Treatment and Care (CIS-PD)
  • Clinician-input Study: How the Fox Wearable Companion Mobile Application can Influence Treatment and Care (CIS-PD)
  • DWI and Olfaction as PD a Biomarker
  • Defining Alpha-Synuclein Conformers Responsible for PD Phenotypes in Mice
  • Expansion Microscopy to Visualize Intracellular aSyn Pathology
  • Fox Investigation for New Discovery of Biomarkers (BioFIND)
  • Identification of Robust and Relevant Pre-Clinical Phenotypes for LRRK2 Therapeutics
  • Investigating the Phenotype of B-Cells in Peripheral Blood of PD Patients
  • MJFF Emerging Targets Committee Membership
  • MOU - LRRK2 Consortium Memorandum of Understanding
  • Mechanisms of LRRK2 Membrane Association
  • Seeking Neuro-Protection Via a Novel Complex-1 Chaperone Supplement
  • Targeting MHCII Proteins on CNS Resident Microglia in an Alpha-Synuclein Model of Parkinson Disease
  • Targeting the JAK/STAT Pathway in the Treatment of Parkinson's Disease
  • Targeting the JAK/STAT Pathway in the Treatment of Parkinson's Disease
  • The Edmond J. Safra Fellowship in Movement Disorders
  • The Edmond J. Safra Fellowship in Movement Disorders 2019 Program
  • The Parkinson's Progression Marker's Initiative (PPMI)
  • The Role of the JAK/STAT Pathway in Human Parkinson's Disease
  • The Systemic Synuclein Sampling Study (S4)
  • Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's Disease
  • Unfolded Protein Response (UPR) Perk Signaling in Parkinson's Disease Progression
  • University of Alabama at Birmingham_The Edumond J. Safra Fellowship in Movement Disorders 2017
  • Unlocking Dystonia from Parkinson's Disease with Directional DBS Technology
  • Utilizing Transcriptional Pathways to Enhance Mitochondrial Health in Models of PD
  • Validation of CCR2-Dependent Monocyte Entry in Alpha-Synuclein-Induced Toxicity
  • Validation of CCR2-Dependent Monocyte Entry in Alpha-Synuclein-lnduced Toxicity
  • Validation of CD4 T cell Dependent Neurotoxicity in an Alpha-synuclein Model of PD
  • Validation of Dyskinesis Rating Scales
  • Validation of the Class II MHC Transactivator (CIITA) in Models of PD